With at least 2 studies in the metastatic setting supporting the superiority of the weekly paclitaxel regime (RR/DFS/OS) it was considered that 3 weekly paclitaxel is an inferior regime in the treatment of breast cancer and should not be used in the adjuvant setting. If a 3 weekly regime is preferable then consideration should be given to a docetaxel containing regime."

Version 2

This protocol is discontinued as it is inferior to other alternatives in the adjuvant setting.

27/04/2012

Protocol reviewed at Medical Oncology Reference Committee meeting.
No change and next review in 2 years.

31/05/2017

Transferred to new eviQ website.

The information contained in this protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to treatment. Any clinician (medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse) seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au